Compare Match Group Inc (MTCH) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Natera Inc. Common Stock — how do they compare? Match Group Inc trades at $42.39 (market cap $9.72B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.9× Match Group Inc's market cap, and Match Group Inc pays a 1.89% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Natera Inc. Common Stock for 0 Days on average.
| MTCH | NTRA | |
|---|---|---|
Market Cap | $9.72B | $57.03B |
Volume | 4,140,020 | 1,131,157 |
Sector | Media | Health |
52-Week High | $44.40 | $425.64 |
52-Week Low | $28.90 | $179.42 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $12.69B | $56.18B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $42.40, up 2.12% today, with a bullish technical signal and strong support at $41. The company reported a net income margin of 20.17% for 2025, with Q2 2026 EPS beating expectations. Operating cash flow reached $1.08B in 2025, and a $0.20 dividend is scheduled for October 2026. Recent news highlights product innovation at Tinder and growth at Hinge.
The outlook is positive with a consensus price target of $42.29, though high debt levels and competitive pressures pose risks. Analyst sentiment is bullish with 53% buy ratings. Revenue stability and margin expansion support upside potential, but investors should monitor execution on Tinder's turnaround and debt management.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
